Back to Explorer

CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products - Phase I

FinalCenter for Veterinary Medicine03/07/2001
Environmental Impact Assessments

Description

In 1996, the VICH Steering Committee (VICH SC) authorized formation of a working group to develop harmonized guidance for conducting environmental impact assessments (EIA's) for veterinary medicinal products (VMP's) in the European Union (EU), Japan (JP) and the United States (US).  The mandate of the VICH Ecotoxicity/Environmental Impact Assessment Working Group (VICH Ecotox WG), as set forth by the VICH SC, is as follows:

Key Topics

Terms and concepts identified from this document

Scope & Applicability

Product Classes

1
Veterinary Medicinal Products

International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products

Stakeholders

1
Applicant

Entity submitting development data and knowledge; Entity performing the work process for change

Regulatory Context

Regulatory Activities

2
Phase II

Advanced stage of environmental impact assessment for higher risk products

Phase I

Cancer clinical trials involving dose escalation

Document Types

2
Environmental Impact Assessment

Regulatory documentation required for VMP approval

Environmental Impact Statement

Prepared if significant environmental impacts are identified.

Attributes

2
total residue concept

Summing parent drug and all related metabolites for EIC/PEC calculations

Extensively metabolized

A condition where no single metabolite or parent drug exceeds 5% of total radioactivity excreted.

Technical Details

Substances

3
endoparasiticide

VMP class requiring specific ecotoxicity assessment

ectoparasiticide

VMP class requiring specific ecotoxicity assessment

Natural substance

Substances like electrolytes, peptides, and proteins that may stop at Phase I.

Testing Methods

2
aquatic effects tests

Required in Phase II for parasiticides

Radiolabeled residue depletion and excretion study

Method used to demonstrate extensive metabolism in the treated animal.

Processes

1
Incineration

Acceptable means for disposal of altered animals

Clinical Concepts

2
Minor species

Species reared and treated similarly to major species.

Non-food animals

Animal populations such as pets that are generally not intensively reared.

Identified Hazards

Hazards

2
ecotoxicity

Potential for adverse effects on aquatic or terrestrial organisms

Environmental exposure

The potential risk assessed based on the intended use of the VMP.

Standards & References

External Standards

1
National Environmental Policy Act

FDA has to comply with the environmental review requirements of NEPA

Specifications

2
PECsoil < 100 µg/Kg

Predicted environmental concentration trigger value for soil

EICaquatic < 1 µg/L

Environmental introduction concentration trigger value for aquatic environments

ICH References (1)

VICH GL6

Harmonized methods for conducting environmental assessments for veterinary medicinal products.

Related CFR Sections (2)

See Also (8)

CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products - Phase I | Guideline Explorer | BioRegHub